



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Neil H. Bander
Serial No. : 09/357,704
Filed : July 20, 1999
Title : TREATMENT AND DIAGNOSIS OF PROSTATE CANCER
Art Unit : 1643
Examiner : Stephen L. Rawlings
Conf. No. : 9622

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicant requests consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request.

This statement is being filed after a first Office action on the merits, but before receipt of a final Office action or a Notice of Allowance. A check for \$180 in payment of the late submission fee of §1.17(p) is enclosed. Please apply any other charges or credits to Deposit Account No. 06-1050, referencing Attorney's Docket Number 21052-003002.

Respectfully submitted,

Date: 7/19/07

Laurie Lawrence
Laurie Butler Lawrence
Reg. No. 46,593

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110
Telephone: (617) 542-5070
Facsimile: (617) 542-8906
21661252.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Date of Deposit

Signature

Typed or Printed Name of Person Signing Certificate

02 FC:1806

180.00 OP

Substitute Form PTO-1449 (Modified)  Information Disclosure Statement by Applicant (Use several sheets if necessary)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 21052-003002	Application No. 09/357,704
	Applicant Neil H. Bander		
	Filing Date July 20, 1999	Group Art Unit 1643	

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	08/621,399		Murphy et al			
	AB	2004/0120958	06-2004	Bander et al.			
	AC	2004/0213791	10-2004	Bander et al.			
	AD	US 6,649,163	11-2003	Bander, Neil H.			
	AE	US 7,045,605	05-2006	Bander et al.			
	AF	US 6,683,162	01-2004	Scheinberg et al.			
	AG	US 7,163,680	01/2007	Bander, Neil H			
	AH						
	AI						

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AJ	0 125 023A1	11-1984	Europe				
	AK	WO 96/08570	03/21/1996	WIPO				
	AL	WO91/07493	05-1991	WIPO				
	AM							
	AN							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AO	Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185 ^{HER2} Monoclonal Antibody in Patients with HER2/NEU-Overexpressing Metastatic Breast Cancer" J. Clin. Oncol, 14:737-744, 1996.
	AP	Campbell et al. "Monoclonal antibody therapy for lymphoma", Blood Reviews 17:143-152, 2003.
	AQ	Clamp and Jayson, "The clinical potential of antiangiogenic fragments of extracellular matrix proteins" British Journal of Cancer, 93:967-972, 2005.
	AR	Curti, "Physical barriers to drug delivery in tumors, Crit. Rev. in Oncology/Hematology, 14: 29-39, 1993.
	AS	Dennis, "Off by a whisker", Nature.; 442: 739-741, 2006.
	AT	Dillman, "Monoclonal Antibodies for Treating Cancer" Annals of Internal Medicine, 111:592-603, 1989.

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 21052-003002 Applicant Neil H. Bander Filing Date July 20, 1999	Application No. 09/357,704 Group Art Unit 1643
--	--	--	---

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AU	Gura, "Systems for Identifying New Drugs Are Often Faulty" Science, 278:1041-1042, 1997.
	AV	Hopp et al., "A Computer Program for Predicting Protein Antigenic Determinants", Mol. Immunol. 20:4pp.483-489, 1983.
	AW	Israeli et al., "Molecular Cloning of a Complementary DNA Encoding a Prostate-Specific Membrane Antigen", Cancer Research 53, 227-230, January 15, 1993 (Cited in EP Opposition of 12/19/2006.
	AX	Jain, "Barriers to Drug Delivery in Solid Tumors" Scientific American 271:58-65, 1994.
	AY	Janeway and Travers, Immuno Biology 3 rd Ed. (1997), extracts from chapter 3 pages 3:23-24, chapter 8, pages 8:18-19, and chapter 13, pages 13:17-19.
	AZ	Kaiser, "First Pass at Cancer Genome Reveals Complex Landscape" Science 313:1370, 2006.
	AAA	Kipps et al., "Importance of Immunoglobulin Isotype in Human antibody-Dependent, Cell-Mediated Cytotoxicity Directed by Murine Monoclonal Antibodies" J. Exp. Med., 161(1): 1-17, 1985.
	ABB	Masui et al., "Mechanism of Antitumor Activity in Mice for Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies with Different Isotypes" Cancer Res, 46 (11):5592-5598, 1986.
	ACC	Mwawech-Fauceglia, et al., "Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using multiple tumour tissue microarray technique" Histopathology., 50(4):472-483. 2007.
	ADD	Persiani et al., "In vivo antitumor effect of methotrexate conjugated to a monoclonal IgM antibody specific for stage-specific embryonic antigen-1, on MH-15 mouse teratocarcinoma", Cancer Immunol Immunother, 29:167-170, 1989.
	AEE	Rajasekaran et al., "A Novel Cytoplasmic Tail MXXXL Motif Mediates the Internalization of Prostate-specific Membrane Antigen", Molecular Biology of the Cell, 14: 4835-4845, 2003.
	AFF	Silver D. A. et al., "Prostate-specific Membrane Antigen Expression in Normal and Malignant Human Tissues", Clinical Cancer Research, 3:81-85, 1997.
	AGG	Tazzari et al., "An immunotoxin containing a rat IgM monoclonal antibody (Campath 1) and a saporin 6: effect on T lymphocytes and hemopoietic cells", Cancer Immunol Immunother, 26:231-236, 1988.
	AHH	Usui et al., "Evaluation of Ricin a Chain-Containing Immunotoxins Directed Against Glycolipid and Glycoprotein on Mouse Lymphoma Cells", Acta Med Okayama, 48(6):305-309, 1994.
	AII	Vuist et al., "Two distinct Mechanisms of Antitumor Activity Mediated by the Combination of Interleukin 2 and Monoclonal Antibodies" Cancer Res., 50 (18):5767-5772, 1990.
	AJJ	Weiner, "An Overview of Monoclonal Antibody Therapy of Cancer", <i>Seminars Oncology</i> 26:41-50 (1999)
	AKK	Wiedlocha et al., "Specific Killing of Mouse Leukemic Cells with Ricin A-Chain Immunotoxin", Archivum Immunologiae et Therapiac Experimentalis, 37:101-113, 1989.
	ALL	Wiels et al., "Properties of Immunotoxins against a Glycolipid Antigen Associated with Burkitt's Lymphoma", Cancer Research, 44:129-133, 1984.
	AMM	Winter et al. "Humanized antibodies" TIPS, 14:139-143, 1993.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	